US6500948B1
(en)
|
1995-12-08 |
2002-12-31 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
|
HUP9902092A3
(en)
*
|
1995-12-08 |
2000-12-28 |
Agouron Pharmaceuticals Inc La |
Metalloproteinase inhibitor benzenesulfonamide derivatives, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
|
PT871439E
(pt)
*
|
1996-01-02 |
2004-08-31 |
Aventis Pharma Inc |
Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo)
|
KR20000022532A
(ko)
*
|
1996-06-27 |
2000-04-25 |
오노 야꾸힝 고교 가부시키가이샤 |
아릴(설파이드, 설폭시드 및 설폰)유도체 및 이를 활성 성분으로 함유하는 약물
|
EP0818442A3
(en)
*
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
US6118001A
(en)
*
|
1996-08-07 |
2000-09-12 |
Darwin Discovery, Ltd. |
Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
|
US6566384B1
(en)
|
1996-08-07 |
2003-05-20 |
Darwin Discovery Ltd. |
Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
|
TR199900382T2
(xx)
*
|
1996-08-28 |
1999-05-21 |
The Procter & Gamble Company |
Heterosiklik metaloproteaz inhibit�rleri.
|
UA48262C2
(ru)
*
|
1996-09-27 |
2002-08-15 |
Фармація Енд Апджон Компані |
b-СУЛЬФОНИЛ ГИДРОКСАМОВЫЕ КИСЛОТЫ КАК ИНГИБИТОРЫ МАТРИЧНЫХ МЕТАЛЛОПРОТЕИНАЗ, ПРОМЕЖУТОЧНОЕ СОЕДИНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
|
WO1998016227A1
(en)
|
1996-10-15 |
1998-04-23 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
|
US5929097A
(en)
*
|
1996-10-16 |
1999-07-27 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
US6228869B1
(en)
|
1996-10-16 |
2001-05-08 |
American Cyanamid Company |
Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
US6548524B2
(en)
|
1996-10-16 |
2003-04-15 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
US5977408A
(en)
*
|
1996-10-16 |
1999-11-02 |
American Cyanamid Company |
Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
US5962481A
(en)
*
|
1996-10-16 |
1999-10-05 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
PT950059E
(pt)
*
|
1997-01-06 |
2004-10-29 |
Pfizer |
Derivados de sulfona ciclicos
|
DE69829648T2
(de)
*
|
1997-01-22 |
2009-12-10 |
Aventis Pharmaceuticals Inc. |
Substituierte β-Thiocarbonsäure
|
ZA98376B
(en)
*
|
1997-01-23 |
1998-07-23 |
Hoffmann La Roche |
Sulfamide-metalloprotease inhibitors
|
EA002810B1
(ru)
*
|
1997-01-23 |
2002-10-31 |
Ф.Хоффманн-Ля Рош Аг |
Сульфамидные ингибиторы металлопротеаз
|
CA2279863A1
(en)
*
|
1997-02-07 |
1998-08-13 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
US6362183B1
(en)
|
1997-03-04 |
2002-03-26 |
G. D. Searle & Company |
Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
|
US7115632B1
(en)
|
1999-05-12 |
2006-10-03 |
G. D. Searle & Co. |
Sulfonyl aryl or heteroaryl hydroxamic acid compounds
|
US6696449B2
(en)
|
1997-03-04 |
2004-02-24 |
Pharmacia Corporation |
Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
|
WO1998039315A1
(en)
*
|
1997-03-04 |
1998-09-11 |
Monsanto Company |
Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
|
US6794511B2
(en)
|
1997-03-04 |
2004-09-21 |
G. D. Searle |
Sulfonyl aryl or heteroaryl hydroxamic acid compounds
|
ES2206903T3
(es)
*
|
1997-03-04 |
2004-05-16 |
Monsanto Company |
Compuestos sulfonilicos divalentes de acido aril o heteroaril-hidroxamco.
|
WO1998039316A1
(en)
*
|
1997-03-04 |
1998-09-11 |
Monsanto Company |
N-hydroxy 4-sulfonyl butanamide compounds
|
US5985900A
(en)
*
|
1997-04-01 |
1999-11-16 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
US6300514B1
(en)
|
1997-06-25 |
2001-10-09 |
Ono Pharmaceutical Co., Ltd. |
Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
|
EP0997147B1
(en)
|
1997-07-08 |
2006-03-15 |
Ono Pharmaceutical Co., Ltd. |
Amino acid derivatives
|
US6235786B1
(en)
|
1997-08-06 |
2001-05-22 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
US6294573B1
(en)
|
1997-08-06 |
2001-09-25 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
US6130220A
(en)
*
|
1997-10-16 |
2000-10-10 |
Syntex (Usa) Inc. |
Sulfamide-metalloprotease inhibitors
|
JPH11199512A
(ja)
*
|
1997-10-24 |
1999-07-27 |
Pfizer Prod Inc |
変形性関節症および他のmmp媒介疾患の治療のためのmmp−13選択的阻害剤の使用
|
US20010039287A1
(en)
|
1997-11-14 |
2001-11-08 |
Thomas E Barta |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
US6750228B1
(en)
|
1997-11-14 |
2004-06-15 |
Pharmacia Corporation |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
NZ503485A
(en)
*
|
1997-11-14 |
2002-10-25 |
G |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
JP2001524462A
(ja)
*
|
1997-11-21 |
2001-12-04 |
ファーマシア・アンド・アップジョン・カンパニー |
マトリックスメタロプロテイナーゼインヒビターとしてのβ−スルホニルヒドロキサム酸のα−ヒドロキシ、−アミノ及びハロ誘導体
|
GB9725782D0
(en)
*
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
GB9801690D0
(en)
*
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
AU751780B2
(en)
*
|
1998-02-06 |
2002-08-29 |
Darwin Discovery Limited |
Hydroxamic and carboxylic acid derivatives
|
US6680338B2
(en)
*
|
1998-02-06 |
2004-01-20 |
Darwin Discovery Ltd. |
Hydroxamic and carboxylic acid derivatives
|
PA8469401A1
(es)
*
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
AU4074799A
(en)
*
|
1998-05-14 |
1999-11-29 |
Du Pont Pharmaceuticals Company |
Substituted aryl hydroxamic acids as metalloproteinase inhibitors
|
EP0967201A1
(en)
*
|
1998-05-20 |
1999-12-29 |
Roche Diagnostics GmbH |
Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
|
EP1087937A1
(en)
|
1998-06-17 |
2001-04-04 |
Du Pont Pharmaceuticals Company |
Cyclic hydroxamic acids as metalloproteinase inhibitors
|
EP1357109B1
(en)
|
1998-06-18 |
2008-07-23 |
F. Hoffmann-La Roche Ag |
Process for aryl alkyl sulfide
|
TWI245035B
(en)
|
1998-06-26 |
2005-12-11 |
Ono Pharmaceutical Co |
Amino acid derivatives and a pharmaceutical composition comprising the derivatives
|
US6903119B1
(en)
|
1998-07-14 |
2005-06-07 |
Ono Pharmaceutical Co., Ltd. |
Amino acid derivatives and drugs containing the same as the active ingredient
|
CA2348459A1
(en)
*
|
1998-11-12 |
2000-05-25 |
Darwin Discovery Limited |
Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
|
US20040122011A1
(en)
*
|
1998-12-23 |
2004-06-24 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
|
EP1147085B1
(en)
*
|
1999-01-27 |
2005-11-16 |
Wyeth Holdings Corporation |
Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors
|
CO5150194A1
(es)
*
|
1999-01-27 |
2002-04-29 |
Abbott Lab |
Inhibidores hidroxamato inversos de las metalopreteinasas matriciales
|
US6753337B2
(en)
*
|
1999-01-27 |
2004-06-22 |
Wyeth Holdings Corporation |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
EE200100410A
(et)
|
1999-02-08 |
2002-12-16 |
G.D. Searle & Co. |
Sulfamaathüdroksaamhappe metalloproteaasi inhibiitor
|
US6800646B1
(en)
|
1999-02-08 |
2004-10-05 |
Pharmacia Corporation |
Sulfamato hydroxamic acid metalloprotease inhibitor
|
US6583299B1
(en)
*
|
1999-05-20 |
2003-06-24 |
G.D. Searle & Co. |
α-amino-β-sulfonyl hydroxamic acid compounds
|
GB9912961D0
(en)
*
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
US6511993B1
(en)
|
1999-06-03 |
2003-01-28 |
Kevin Neil Dack |
Metalloprotease inhibitors
|
US6869951B1
(en)
|
1999-07-16 |
2005-03-22 |
Pharmacia Corporation |
Method of changing conformation of a matrix metalloproteinase
|
AU779298B2
(en)
*
|
1999-08-16 |
2005-01-13 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of proteinase inhibitor in order to inhibit the cleavage of growth factor precursor
|
US7632645B1
(en)
|
1999-08-16 |
2009-12-15 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF
|
UA74803C2
(ru)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стойкий полиморф гидрохлорида n-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина, способ его получения (варианты) и фармацевтическое применение
|
MXPA02009020A
(es)
|
2000-03-17 |
2003-02-12 |
Du Pont Pharm Co |
Derivados de beta-aminoacidos ciclicos como inhibidores de las metaloproteasas de matriz y factor de necrosis de tumor alfa.
|
AU2001250850A1
(en)
|
2000-03-17 |
2001-10-03 |
Dupont Pharmaceuticals Company |
Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
|
EP1138680A1
(en)
*
|
2000-03-29 |
2001-10-04 |
Pfizer Products Inc. |
Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
|
US6683093B2
(en)
|
2000-05-12 |
2004-01-27 |
Pharmacia Corporation |
Aromatic sulfone hydroxamic acids and their use as protease inhibitors
|
JP2003533513A
(ja)
|
2000-05-15 |
2003-11-11 |
ダーウィン・ディスカバリー・リミテッド |
Mmpおよびtnf阻害活性を有するヒドロキサム酸およびカルボン酸誘導体
|
US6469020B2
(en)
|
2000-05-15 |
2002-10-22 |
Darwin Discovery, Ltd. |
Hydroxamic and carboxylic acid derivatives
|
US6927216B2
(en)
|
2000-10-03 |
2005-08-09 |
Bristol-Myers Squibb Pharma Company |
Cyclic sulfonyl compounds as inhibitors of metalloproteases
|
OA12589A
(en)
|
2001-01-05 |
2006-06-08 |
Abgenix Inc |
Antibodies to insulin-like growth factor i receptor.
|
AU2002246983A1
(en)
|
2001-01-11 |
2002-07-24 |
Bristol-Myers Squibb Pharma Company |
1,2-disubstituted cyclic inhibitors of matrix metallorproteases and tnf-alpha
|
CA2434205A1
(en)
|
2001-01-11 |
2002-07-18 |
Dupont Pharmaceuticals Company |
1,1-disubstituted cyclic inhibitors of matrix metalloprotease and tnf-.alpha.
|
AU2002258507A1
(en)
|
2001-03-15 |
2002-10-03 |
Bristol-Myers Squibb Company |
Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteinases and tnf-alpha converting enzyme (tage)
|
IL158454A0
(en)
|
2001-05-11 |
2004-05-12 |
Pharmacia Corp |
Aromatic sulfone hydroxamates and their use as protease inhibitors
|
US6995171B2
(en)
|
2001-06-21 |
2006-02-07 |
Agouron Pharmaceuticals, Inc. |
Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
|
US6683078B2
(en)
|
2001-07-19 |
2004-01-27 |
Pharmacia Corporation |
Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
PE20030701A1
(es)
|
2001-12-20 |
2003-08-21 |
Schering Corp |
Compuestos para el tratamiento de trastornos inflamatorios
|
CA2471814C
(en)
|
2001-12-27 |
2011-03-15 |
Sumitomo Pharmaceuticals Co., Ltd. |
Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
|
US7006585B2
(en)
*
|
2001-12-31 |
2006-02-28 |
Texas Instruments Incorporated |
Recovering data encoded in serial communication channels
|
NZ535158A
(en)
|
2002-03-13 |
2007-06-29 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
US20050209278A1
(en)
*
|
2002-04-25 |
2005-09-22 |
Mcdonald Joseph J |
Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
|
WO2003091247A2
(en)
|
2002-04-25 |
2003-11-06 |
Pharmacia Corporation |
Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
JP2006502980A
(ja)
*
|
2002-06-25 |
2006-01-26 |
ファルマシア・コーポレーション |
アリールスルホニルヒドロキサム酸およびアミド誘導体、ならびにプロテアーゼ阻害薬としてのそれらの使用
|
MXPA05006676A
(es)
|
2002-12-19 |
2005-08-16 |
Pfizer |
Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso.
|
JP2006516548A
(ja)
|
2002-12-30 |
2006-07-06 |
アンジオテック インターナショナル アクツィエン ゲゼルシャフト |
迅速ゲル化ポリマー組成物からの薬物送達法
|
NZ541861A
(en)
|
2003-02-26 |
2009-05-31 |
Sugen Inc |
Aminoheteroaryl compounds as protein kinase inhibitors
|
ES2369498T3
(es)
|
2003-04-04 |
2011-12-01 |
Yeda Research And Development Co., Ltd. |
Anticuerpos para inhibir la actividad de mmp-2 y mmp-9.
|
US7008953B2
(en)
|
2003-07-30 |
2006-03-07 |
Agouron Pharmaceuticals, Inc. |
3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
GB0325836D0
(en)
*
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
WO2005051906A2
(en)
|
2003-11-19 |
2005-06-09 |
Array Biopharma Inc. |
Heterocyclic inhibitors of mek and methods of use thereof
|
DE602004028150D1
(de)
*
|
2003-11-26 |
2010-08-26 |
Pfizer Prod Inc |
Aminopyrazolderivate als gsk-3-inhibitoren
|
CN101001834B
(zh)
|
2004-03-22 |
2011-06-29 |
南方研究院 |
基质金属蛋白酶的非肽抑制剂
|
US20050277897A1
(en)
*
|
2004-06-14 |
2005-12-15 |
Ghannoum Ziad R |
Handpiece tip
|
WO2006008639A1
(en)
|
2004-07-16 |
2006-01-26 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
|
WO2006021884A2
(en)
|
2004-08-26 |
2006-03-02 |
Pfizer Inc. |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
US8436190B2
(en)
|
2005-01-14 |
2013-05-07 |
Cephalon, Inc. |
Bendamustine pharmaceutical compositions
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
GB0505756D0
(en)
*
|
2005-03-21 |
2005-04-27 |
Mars Uk Ltd |
Method
|
CN101166524B
(zh)
|
2005-04-28 |
2010-12-22 |
辉瑞有限公司 |
氨基酸衍生物
|
US8299076B2
(en)
|
2005-05-18 |
2012-10-30 |
Array Biopharma Inc. |
Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
JP5055284B2
(ja)
|
2005-09-20 |
2012-10-24 |
オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー |
インシュリン様成長因子−1受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
|
WO2007121269A2
(en)
|
2006-04-11 |
2007-10-25 |
Ardea Biosciences, Inc. |
N-aryl-n'alkyl sulfamides as mek inhibitors
|
JP5269762B2
(ja)
|
2006-04-18 |
2013-08-21 |
アーディア・バイオサイエンシーズ・インコーポレイテッド |
Mek阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド
|
EP2041181B1
(en)
*
|
2006-06-08 |
2011-05-18 |
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Specific protease inhibitors and their use in cancer therapy
|
WO2008001959A1
(fr)
|
2006-06-28 |
2008-01-03 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Nouveau dérivé hétérocyclique 6-5 bicyclique et utilisation médicale de celui-ci
|
WO2008075196A1
(en)
|
2006-12-15 |
2008-06-26 |
Pfizer Products Inc. |
Benzimidazole derivatives
|
AU2008206045A1
(en)
|
2007-01-19 |
2008-07-24 |
Ardea Biosciences, Inc. |
Inhibitors of MEK
|
CA2678304A1
(en)
|
2007-02-23 |
2008-08-28 |
Yeda Research And Development Co. Ltd. |
Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
PL2144604T3
(pl)
*
|
2007-02-28 |
2012-02-29 |
Conatus Pharmaceuticals Inc |
Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830
|
UA97834C2
(ru)
|
2007-04-18 |
2012-03-26 |
Пфайзер Продактс Инк. |
Производные сульфониламида для лечения анормального роста клеток
|
JP5479337B2
(ja)
|
2007-07-30 |
2014-04-23 |
アルディア バイオサイエンス,インク. |
Mek阻害剤およびrafキナーゼ阻害剤の組み合わせ、ならびにその使用
|
JP5421925B2
(ja)
|
2007-12-19 |
2014-02-19 |
ジェネンテック, インコーポレイテッド |
5−アニリノイミダゾピリジン及び使用の方法
|
EP2220092B1
(en)
|
2007-12-21 |
2012-06-06 |
Genentech, Inc. |
Azaindolizines and methods of use
|
KR101897881B1
(ko)
|
2008-01-04 |
2018-09-12 |
인텔리카인, 엘엘씨 |
특정 화학 물질, 조성물 및 방법
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
AR072777A1
(es)
|
2008-03-26 |
2010-09-22 |
Cephalon Inc |
Formas solidas de clorhidrato de bendamustina
|
EP2271347B1
(en)
|
2008-03-28 |
2016-05-11 |
Hale Biopharma Ventures, Llc |
Administration of benzodiazepine compositions
|
CN102124009B
(zh)
|
2008-07-08 |
2014-07-23 |
因特利凯公司 |
激酶抑制剂及其使用方法
|
RU2503681C2
(ru)
*
|
2008-09-30 |
2014-01-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Новое конденсированное производное аминодигидротиазина
|
WO2010045495A2
(en)
|
2008-10-16 |
2010-04-22 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
IL271761B
(en)
|
2009-02-05 |
2022-09-01 |
Immunogen Inc |
(12as)-8-methoxy-9-benzyloxy-11,12,12a,13-tetrahydro-6h-indolo[2,1-c][1,4]benzodiazepine-6-one, 4-benzyloxy-5-methoxy -2-nitrobenzoic acid and a process for their preparation
|
CN102307875A
(zh)
|
2009-02-09 |
2012-01-04 |
苏伯俭股份有限公司 |
吡咯并嘧啶基axl激酶抑制剂
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US20100222381A1
(en)
|
2009-02-27 |
2010-09-02 |
Hariprasad Vankayalapati |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2411366B8
(en)
|
2009-03-27 |
2015-07-15 |
Ardea Biosciences, Inc. |
Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン, エルエルシー |
複素環式化合物およびその使用
|
EP2459191A1
(en)
|
2009-07-31 |
2012-06-06 |
OSI Pharmaceuticals, LLC |
Mtor inhibitor and angiogenesis inhibitor combination therapy
|
IN2012DN01961A
(ru)
|
2009-08-17 |
2015-08-21 |
Intellikine Llc |
|
WO2011027249A2
(en)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Benzimidazole derivatives
|
US9034861B2
(en)
|
2009-10-13 |
2015-05-19 |
Allomek Therapeutics Llc |
MEK inhibitors useful in the treatment of diseases
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
AP2012006294A0
(en)
|
2009-11-05 |
2012-06-30 |
Rhizen Pharmaceuticals Sa |
Novel kinase modulators.
|
TW201129384A
(en)
|
2010-02-10 |
2011-09-01 |
Immunogen Inc |
CD20 antibodies and uses thereof
|
US8754072B2
(en)
|
2010-02-12 |
2014-06-17 |
Pfizer Inc. |
Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
|
US20110275644A1
(en)
|
2010-03-03 |
2011-11-10 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
CA2783665A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
CN103068824B
(zh)
|
2010-05-17 |
2017-09-08 |
印蔻真治疗公司 |
作为蛋白激酶调节剂的新型3,5‑二取代‑3h‑咪唑并[4,5‑b]吡啶和3,5‑二取代‑3h‑[1,2,3]三唑并[4,5‑b]吡啶化合物
|
EP2571357B1
(en)
|
2010-05-21 |
2016-07-06 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
JP2013538042A
(ja)
|
2010-06-16 |
2013-10-10 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
エンドプラスミンに対する抗体およびその使用
|
JP5802756B2
(ja)
|
2010-10-20 |
2015-11-04 |
ファイザー・インク |
スムーズンド受容体モジュレーターとしてのピリジン−2−誘導体
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2012080050A1
(en)
*
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
US8809349B2
(en)
|
2011-01-10 |
2014-08-19 |
Infinity Pharmaceuticals, Inc. |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
WO2012106556A2
(en)
|
2011-02-02 |
2012-08-09 |
Amgen Inc. |
Methods and compositons relating to inhibition of igf-1r
|
US9534000B2
(en)
|
2011-02-15 |
2017-01-03 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives and methods of preparation
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
JP5808826B2
(ja)
|
2011-02-23 |
2015-11-10 |
インテリカイン, エルエルシー |
複素環化合物およびその使用
|
AU2011360973A1
(en)
*
|
2011-03-02 |
2013-09-19 |
Aquilus Pharmaceuticals, Inc. |
Compounds and methods for the treatment of pain and other disorders
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
EP3536708A1
(en)
|
2011-04-19 |
2019-09-11 |
Pfizer Inc |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
WO2012151525A1
(en)
|
2011-05-04 |
2012-11-08 |
Rhizen Pharmaceuticals Sa |
Novel compounds as modulators of protein kinases
|
EP2720699B1
(en)
|
2011-06-14 |
2018-05-16 |
Hale Biopharma Ventures, Llc |
Administration of benzodiazepine
|
CN103930422A
(zh)
|
2011-07-19 |
2014-07-16 |
无限药品股份有限公司 |
杂环化合物及其用途
|
JP6027611B2
(ja)
|
2011-07-19 |
2016-11-16 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
ES2671748T3
(es)
|
2011-07-21 |
2018-06-08 |
Tolero Pharmaceuticals, Inc. |
Inhibidores heterocíclicos de proteína quinasas
|
AU2012302197B2
(en)
|
2011-08-29 |
2016-01-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
BR112014006840A2
(pt)
|
2011-09-22 |
2017-04-04 |
Pfizer |
derivados de pirrolopirimidina e purina
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
ES2654160T3
(es)
|
2011-10-04 |
2018-02-12 |
Igem Therapeutics Limited |
Anticuerpos de IgE anti-HMW-MAA
|
KR20140076602A
(ko)
|
2011-11-08 |
2014-06-20 |
화이자 인코포레이티드 |
항-m-csf 항체를 사용한 염증성 장애의 치료 방법
|
US9452215B2
(en)
|
2012-02-22 |
2016-09-27 |
The Regents Of The University Of Colorado |
Bourvadin derivatives and therapeutic uses thereof
|
EP3345624A1
(en)
|
2012-02-22 |
2018-07-11 |
The Regents Of The University Of Colorado |
Bouvardin derivatives and therapeutic uses thereof
|
BR112014024251A8
(pt)
|
2012-03-30 |
2018-01-23 |
Rhizen Pharmaceuticals S A |
novos compostos piridina 3,5-dissubstituída-3h-imidazo [4,5-b] e piridina 3,5-dissubstituída -3h-[1,2,3]triazolo[4,5-b] como moduladores de quinases de proteína c-met
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP2859017B1
(en)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
DK2863955T3
(en)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
|
WO2014031566A1
(en)
|
2012-08-22 |
2014-02-27 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
EP3584255B1
(en)
|
2012-08-31 |
2022-02-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
DK2909181T3
(da)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
RS58023B2
(sr)
|
2012-11-01 |
2021-12-31 |
Infinity Pharmaceuticals Inc |
Lečenje kancera korišćenjem modulatora izoformi pi3 kinaza
|
GB201302755D0
(en)
|
2013-02-15 |
2013-04-03 |
Mars Inc |
Horse supplement
|
US9901647B2
(en)
|
2013-02-28 |
2018-02-27 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP2961434A2
(en)
|
2013-02-28 |
2016-01-06 |
ImmunoGen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
KR102334260B1
(ko)
|
2013-03-14 |
2021-12-02 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Jak2 및 alk2 억제제 및 이들의 사용 방법
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
WO2014151386A1
(en)
|
2013-03-15 |
2014-09-25 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
MX364438B
(es)
|
2013-03-15 |
2019-04-26 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
AU2014273946B2
(en)
|
2013-05-30 |
2020-03-12 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using PI3 kinase isoform modulators
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
SG11201602572YA
(en)
|
2013-10-03 |
2016-04-28 |
Kura Oncology Inc |
Inhibitors of erk and methods of use
|
JP6466924B2
(ja)
|
2013-10-04 |
2019-02-06 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
EP3055290B1
(en)
|
2013-10-10 |
2019-10-02 |
Araxes Pharma LLC |
Inhibitors of kras g12c
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
WO2015107139A1
(en)
|
2014-01-17 |
2015-07-23 |
Proyecto De Biomedicina Cima, S.L. |
Compounds for use as antifibrinolytic agents
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
RS59617B1
(sr)
|
2014-04-30 |
2020-01-31 |
Pfizer |
Cikloalkil-vezani diheterociklični derivati
|
EA034691B1
(ru)
|
2014-06-19 |
2020-03-06 |
Ариад Фармасьютикалз, Инк. |
Гетероарильные соединения для ингибирования киназ
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
EP3473271B1
(en)
|
2014-07-31 |
2022-07-20 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Human monoclonal antibodies against epha4 and their use
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
WO2016049524A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP3233829B1
(en)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
BR112017021869A2
(pt)
|
2015-04-10 |
2018-12-11 |
Araxes Pharma Llc |
compostos quinazolina substituídos e métodos de uso dos mesmos
|
EP3283462B1
(en)
|
2015-04-15 |
2020-12-02 |
Araxes Pharma LLC |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
AU2016252609B2
(en)
|
2015-04-20 |
2022-06-30 |
Sumitomo Pharma Oncology, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
WO2016178876A2
(en)
|
2015-05-01 |
2016-11-10 |
Cocrystal Pharma, Inc. |
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
CN107849073B
(zh)
|
2015-05-18 |
2020-04-03 |
特雷罗药物股份有限公司 |
具有增加的生物利用度的阿伏西地前药
|
TWI703150B
(zh)
|
2015-06-04 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
用於抑制menin及mll蛋白之交互作用的方法及組合物
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
KR20180034538A
(ko)
|
2015-08-03 |
2018-04-04 |
톨레로 파마수티컬스, 인크. |
암의 치료를 위한 병행 요법
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
JP2018533939A
(ja)
|
2015-10-19 |
2018-11-22 |
アラクセス ファーマ エルエルシー |
Rasの阻害剤をスクリーニングするための方法
|
CN108779097A
(zh)
|
2015-11-16 |
2018-11-09 |
亚瑞克西斯制药公司 |
包含取代的杂环基的2-取代的喹唑啉化合物及其使用方法
|
KR20180100125A
(ko)
|
2015-12-03 |
2018-09-07 |
아지오스 파마슈티컬스 아이엔씨. |
Mtap 널 암을 치료하기 위한 mat2a 억제제
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
RU2018130757A
(ru)
|
2016-01-27 |
2020-02-27 |
Сутро Биофарма, Инк. |
Конъюгаты антитела к cd74, композиции, содержащие конъюгаты антитела к cd74, и способы использования конъюгатов антитела к cd74
|
WO2017161002A1
(en)
|
2016-03-16 |
2017-09-21 |
Kura Oncology, Inc. |
Bridged bicyclic inhibitors of menin-mll and methods of use
|
SI3429591T1
(sl)
|
2016-03-16 |
2023-07-31 |
Kura Oncology, Inc. |
Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
EP3454945B1
(en)
|
2016-05-12 |
2022-01-19 |
The Regents Of The University Of Michigan |
Ash1l inhibitors and methods of treatment therewith
|
US11118233B2
(en)
|
2016-05-18 |
2021-09-14 |
The University Of Chicago |
BTK mutation and ibrutinib resistance
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
CA3035081A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
CN110036010A
(zh)
|
2016-09-29 |
2019-07-19 |
亚瑞克西斯制药公司 |
Kras g12c突变蛋白的抑制剂
|
JP2019534260A
(ja)
|
2016-10-07 |
2019-11-28 |
アラクセス ファーマ エルエルシー |
Rasの阻害剤としての複素環式化合物およびその使用方法
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
MX2019007332A
(es)
|
2016-12-19 |
2019-11-18 |
Tolero Pharmaceuticals Inc |
Péptidos indicadores y métodos para caracterizar sensibilidad.
|
JOP20190154B1
(ar)
|
2016-12-22 |
2022-09-15 |
Amgen Inc |
بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
EP3573967A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
US20200385364A1
(en)
|
2017-01-26 |
2020-12-10 |
Araxes Pharma Llc |
Fused n-heterocyclic compounds and methods of use thereof
|
JP7117311B2
(ja)
|
2017-01-26 |
2022-08-12 |
ゼットリップ ホールディング リミテッド |
Cd47抗原結合単位およびその使用
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
CN110691779B
(zh)
|
2017-03-24 |
2023-10-10 |
库拉肿瘤学公司 |
治疗血液系统恶性肿瘤和尤因肉瘤的方法
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
EP3630746A1
(en)
|
2017-05-25 |
2020-04-08 |
Araxes Pharma LLC |
Compounds and methods of use thereof for treatment of cancer
|
EP3630745A2
(en)
|
2017-05-25 |
2020-04-08 |
Araxes Pharma LLC |
Covalent inhibitors of kras
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
WO2019023316A1
(en)
|
2017-07-26 |
2019-01-31 |
Sutro Biopharma, Inc. |
METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
|
EP4141005B1
(en)
|
2017-09-08 |
2024-04-03 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
KR20200051802A
(ko)
|
2017-09-18 |
2020-05-13 |
서트로 바이오파마, 인크. |
항-엽산 수용체 알파 항체 접합체 및 이의 용도
|
WO2019060365A1
(en)
|
2017-09-20 |
2019-03-28 |
Kura Oncology, Inc. |
SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
|
WO2019094773A1
(en)
|
2017-11-10 |
2019-05-16 |
The Regents Of The University Of Michigan |
Ash1l inhibitors and methods of treatment therewith
|
BR112020020246A8
(pt)
|
2018-04-05 |
2022-10-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de cinase axl e uso dos mesmos
|
MX2020010836A
(es)
|
2018-05-04 |
2021-01-08 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso.
|
WO2019213526A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
MA52564A
(fr)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
MA52765A
(fr)
|
2018-06-01 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
CN112533581A
(zh)
|
2018-06-07 |
2021-03-19 |
密歇根大学董事会 |
Prc1抑制剂及用其进行治疗的方法
|
MA52780A
(fr)
|
2018-06-11 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
MA51848A
(fr)
|
2018-06-12 |
2021-04-21 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
EP3826684A4
(en)
|
2018-07-26 |
2022-04-06 |
Sumitomo Dainippon Pharma Oncology, Inc. |
METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE THEREOF
|
AU2019312670A1
(en)
|
2018-08-01 |
2021-02-04 |
Araxes Pharma Llc |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
WO2020060944A1
(en)
|
2018-09-17 |
2020-03-26 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
KR20210083286A
(ko)
|
2018-10-24 |
2021-07-06 |
아락세스 파마 엘엘씨 |
종양 전이를 억제하기 위한 g12c 돌연변이 kras 단백질의 억제제로서 2-(2-아크릴로일-2,6-디아자스피로[3.4]옥탄-6-일)-6-(1h-인다졸-4-일)-벤조니트릴 유도체 및 관련 화합물
|
CA3117221A1
(en)
|
2018-11-16 |
2020-05-22 |
Amgen Inc. |
Improved synthesis of key intermediate of kras g12c inhibitor compound
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
AU2019384118A1
(en)
|
2018-11-19 |
2021-05-27 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
KR20210097715A
(ko)
|
2018-11-29 |
2021-08-09 |
아락세스 파마 엘엘씨 |
암 치료용 화합물 및 이의 사용 방법
|
US11034710B2
(en)
|
2018-12-04 |
2021-06-15 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
MA54546A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
|
CA3123044A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
CN113226473A
(zh)
|
2018-12-20 |
2021-08-06 |
美国安进公司 |
Kif18a抑制剂
|
WO2020132651A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
CA3127502A1
(en)
|
2019-02-12 |
2020-08-20 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
KR20210146287A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로아릴 화합물 및 이의 용도
|
CN113727758A
(zh)
|
2019-03-01 |
2021-11-30 |
锐新医药公司 |
双环杂环基化合物及其用途
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
US11712433B2
(en)
|
2019-03-22 |
2023-08-01 |
Sumitomo Pharma Oncology, Inc. |
Compositions comprising PKM2 modulators and methods of treatment using the same
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
CN114144414A
(zh)
|
2019-05-21 |
2022-03-04 |
美国安进公司 |
固态形式
|
EP3994132A1
(en)
|
2019-07-03 |
2022-05-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
AU2020324963A1
(en)
|
2019-08-02 |
2022-02-24 |
Amgen Inc. |
KIF18A inhibitors
|
AU2020326627A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
KIF18A inhibitors
|
JP2022542392A
(ja)
|
2019-08-02 |
2022-10-03 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤としてのピリジン誘導体
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
WO2021055728A1
(en)
|
2019-09-18 |
2021-03-25 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
TW202126636A
(zh)
|
2019-09-30 |
2021-07-16 |
美商阿吉歐斯製藥公司 |
作為menin抑制劑之六氫吡啶化合物
|
WO2021081212A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
MX2022005053A
(es)
|
2019-10-28 |
2022-05-18 |
Merck Sharp & Dohme Llc |
Inhibidores de peque?as moleculas de mutante g12c de kras.
|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
TW202132314A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras抑制劑
|
BR112022008565A2
(pt)
|
2019-11-04 |
2022-08-09 |
Revolution Medicines Inc |
Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras
|
CN115873020A
(zh)
|
2019-11-04 |
2023-03-31 |
锐新医药公司 |
Ras抑制剂
|
KR20220100903A
(ko)
|
2019-11-08 |
2022-07-18 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로아릴 화합물 및 이의 용도
|
MX2022005708A
(es)
|
2019-11-14 |
2022-06-08 |
Amgen Inc |
Sintesis mejorada del compuesto inhibidor de g12c de kras.
|
AR120456A1
(es)
|
2019-11-14 |
2022-02-16 |
Amgen Inc |
Síntesis mejorada del compuesto inhibidor de g12c de kras
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
AU2021206217A1
(en)
|
2020-01-07 |
2022-09-01 |
Revolution Medicines, Inc. |
SHP2 inhibitor dosing and methods of treating cancer
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
TW202204333A
(zh)
|
2020-04-08 |
2022-02-01 |
美商阿吉歐斯製藥公司 |
Menin抑制劑及治療癌症之使用方法
|
WO2021207310A1
(en)
|
2020-04-08 |
2021-10-14 |
Agios Pharmaceuticals, Inc. |
Menin inhibitors and methods of use for treating cancer
|
EP4139299A1
(en)
|
2020-04-24 |
2023-03-01 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
US20230181536A1
(en)
|
2020-04-24 |
2023-06-15 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
JP2023530351A
(ja)
|
2020-06-18 |
2023-07-14 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Ras阻害剤への獲得耐性を遅延させる、防止する、及び、治療する方法
|
US11858925B2
(en)
|
2020-07-10 |
2024-01-02 |
The Regents Of The University Of Michigan |
GAS41 inhibitors and methods of use thereof
|
WO2022014640A1
(ja)
|
2020-07-15 |
2022-01-20 |
大鵬薬品工業株式会社 |
腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
|
IL301062A
(en)
|
2020-09-03 |
2023-05-01 |
Revolution Medicines Inc |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
AU2021345111A1
(en)
|
2020-09-15 |
2023-04-06 |
Revolution Medicines, Inc. |
Indole derivatives as Ras inhibitors in the treatment of cancer
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
CN117396472A
(zh)
|
2020-12-22 |
2024-01-12 |
上海齐鲁锐格医药研发有限公司 |
Sos1抑制剂及其用途
|
CA3213079A1
(en)
|
2021-04-13 |
2022-10-20 |
Kristin Lynne ANDREWS |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
JP2024519205A
(ja)
|
2021-04-30 |
2024-05-09 |
セルジーン コーポレーション |
抗bcma抗体薬物コンジュゲート(adc)をガンマセクレターゼ阻害剤(gsi)と組み合わせて使用する併用療法
|
CA3217393A1
(en)
|
2021-05-05 |
2022-11-10 |
Elena S. Koltun |
Ras inhibitors
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ras阻害剤及びその使用
|
MX2023013084A
(es)
|
2021-05-05 |
2023-11-17 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cancer.
|
JP2024521979A
(ja)
|
2021-05-28 |
2024-06-04 |
大鵬薬品工業株式会社 |
Kras変異タンパク質の小分子阻害剤関連出願の相互参照
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023056589A1
(en)
|
2021-10-08 |
2023-04-13 |
Servier Pharmaceuticals Llc |
Menin inhibitors and methods of use for treating cancer
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023211812A1
(en)
|
2022-04-25 |
2023-11-02 |
Nested Therapeutics, Inc. |
Heterocyclic derivatives as mitogen-activated protein kinase (mek) inhibitors
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
TW202408589A
(zh)
|
2022-06-30 |
2024-03-01 |
美商舒卓生物製藥公司 |
抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物,及製造及使用抗ror1抗體及抗體結合物之方法
|
WO2024010925A2
(en)
|
2022-07-08 |
2024-01-11 |
Nested Therapeutics, Inc. |
Mitogen-activated protein kinase (mek) inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|